EDSA — Edesa Biotech, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1540159 · Ontario, Canada
Last close
$1.96
Market Cap
$18.90M
52W High
$20.32
52W Low
$0.72
ADV30
3,019,354
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -5,412,181 -5,407,611 12,721,195 10,332,520 3,910,041
Mar 2026 0 — -4,230,766 -4,218,332 12,384,738 10,003,683 2,187,921
Dec 2025 0 — -2,238,958 -2,247,669 14,710,442 12,051,748 756,163
Sep 2025 0 — -2,223,098 -2,228,358 13,530,518 10,792,172 1,078,536

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,907,623
Investing CF
—
Financing CF
$6,979,859
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.62
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-77,896,367
Inventory
—
Receivables
$228,051
ST Investments
—
EBIT TTM
$-14,105,003
Pretax Income TTM
$-14,101,170
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Sep 2025 0 -7,127,672 -7,185,523 13,530,518 1,078,536 12,451,982 -7,322,262
Sep 2024 0 -6,316,467 -6,170,045 3,813,982 1,832,827 1,981,155 -4,890,205
Sep 2023 0 -8,641,719 -8,374,415 8,890,437 1,841,637 7,048,800 -6,636,483
Sep 2022 0 -17,590,533 -17,548,924 11,575,728 2,184,439 9,391,289 -12,279,302

TTM Snapshot

Revenues TTM
$1,152,762
NetIncome TTM
$-14,101,970
OpCashFlow TTM
—
Assets (Latest)
$12,721,195
Forward EPS
$-1.93

Peers — same industry

TickerNameMarket CapLastDaily %
ATOS ATOSSA THERAPEUTICS, INC. $18.96M $1.90 —
CELU Celularity Inc $18.53M $0.57 —
IGC IGC Pharma, Inc. $19.43M $0.19 —
COCP Cocrystal Pharma, Inc. $19.46M $1.01 —
PVCT PROVECTUS BIOPHARMACEUTICALS, INC. $17.90M $0.04 —

News headlines (Yahoo Finance, 1h cache)

Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European Commission
2026-11-17 14:25 · Yahoo
Edesa Biotech Signs Japan Licensing Agreement With Kyorin for Paridiprubart Worth Up to $146 Million
2026-11-09 11:54 · Yahoo
Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan
2026-11-09 11:00 · Yahoo
Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference
2026-11-04 21:30 · Yahoo
Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
2026-10-15 13:15 · Yahoo
EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway
2026-08-24 08:02 · Yahoo
Edesa Biotech Stock Sinks After Fresh Capital Raise
2026-08-20 10:20 · Yahoo
Edesa Biotech Announces Proposed Public Offering
2026-08-19 20:01 · Yahoo
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
2026-08-13 20:15 · Yahoo
EDSA: Positive Exploratory Data in Patients with AKI
2026-07-02 12:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.